Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.
Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, Sieuwerts AM, Lambrechts D, Rutten A, van Dam PA, Pauwels P, Peeters M, Vermeulen PB, Dirix LY. Peeters DJ, et al. Among authors: ignatiadis m. Br J Cancer. 2013 Apr 2;108(6):1358-67. doi: 10.1038/bjc.2013.92. Epub 2013 Mar 7. Br J Cancer. 2013. PMID: 23470469 Free PMC article.
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.
Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis M. Rothé F, et al. Among authors: ignatiadis m. Ann Oncol. 2014 Oct;25(10):1959-1965. doi: 10.1093/annonc/mdu288. Epub 2014 Jul 25. Ann Oncol. 2014. PMID: 25185240 Free article.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014. Salgado R, et al. Among authors: ignatiadis m. Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11. Ann Oncol. 2015. PMID: 25214542 Free PMC article.
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.
Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart M, Sotiriou C. Sonnenblick A, et al. Among authors: ignatiadis m. Oncotarget. 2015 Oct 6;6(30):30306-16. doi: 10.18632/oncotarget.5080. Oncotarget. 2015. PMID: 26358523 Free PMC article. Clinical Trial.
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching PA, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY. Ignatiadis M, et al. Ann Oncol. 2018 Aug 1;29(8):1777-1783. doi: 10.1093/annonc/mdy211. Ann Oncol. 2018. PMID: 29893791 Free article. Clinical Trial.
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M. Solinas C, et al. Among authors: ignatiadis m. Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Cancer Treat Rev. 2017. PMID: 28525810 Review.
Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.
Geukens T, Brandão M, Laenen A, Collignon J, Van Marcke C, Louviaux I, Demey W, Van Wambeke S, Schrijvers D, Lecomte S, Mebis J, Rutten A, Fontaine C, Lybaert W, Aspeslagh S, Goeminne JC, Van Den Bulck H, Seront E, De Backer L, De Roock W, Ignatiadis M, Prenen H, Van Beckhoven D, Heijlen M, Verheezen J, Rottey S, Punie K, de Azambuja E. Geukens T, et al. Among authors: ignatiadis m. ESMO Open. 2022 Dec;7(6):100610. doi: 10.1016/j.esmoop.2022.100610. Epub 2022 Nov 7. ESMO Open. 2022. PMID: 36356416 Free PMC article.
128 results